NuGen Ships First InsuJet(TM) Devices and Consumables to the UK and Attends Diabetes Professional Care Conference

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased to announce that it has delivered its first shipment of InsuJet™ devices and consumables to Reliance Medical Ltd., the Company's UK distributor and 3PL partner in the UK.

NuGen further announces their attendance at the Diabetes Professional Care conference taking place on November 15^th and 16^th 2023, at Olympia, London.

NuGen will be presenting InsuJet™ at Diabetes Professional Care, the UK's leading event for those involved in the prevention, treatment and management of diabetes and its related conditions. The Diabetes Professional Care event attracts over 5,000 healthcare professionals seeking to increase their knowledge and skills to provide better care for people living with diabetes.

"Diabetes Professional Care is an ideal platform for diabetes professionals to discover new innovations and technologies to help improve patient care outcomes and drive health system efficiencies. Presenting InsuJet™ to this professional audience supports NuGen in communicating the benefits of needle-free insulin delivery for diabetic patients and provides us with a platform to engage with diabetes professionals and purchasing decision-makers," Louise Cresswell, Commercial Lead, UK.

Event link: https://www.diabetesprofessionalcare.com.

About NuGen Medical Devices

NuGen is a specialty medical device Company that is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.

For further information, please visit:

Websites: www.insujet.com and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:

Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com

Richard Buzbuzian
President & CEO
(647) 501-3290
richard@nugenmd.com

To arrange a media interview with NuGen, please contact:

Nelson Hudes
Hudes Communications International
(905) 660-9155
nelson@hudescommunications.com

Notice Regarding Forward-Looking Information:

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/172008